Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 530  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14: Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
08/07/2014 > 25 patent applications in 18 patent subcategories.

20140221606 - Aspart proinsulin compositions and methods of producing aspart insulin analogs: Aspart modified proinsulin sequences that have a modified C-peptide amino acid and/or nucleic acid modification for producing aspart insulin analogs are provided. Highly efficient processes for preparing the aspart insulin analogs and improved preparations containing the aspart insulin analogs prepared according to the methods described herein are also provided.... Agent: Elona Biotechnologies Inc.

20140221608 - Acid-cleavable linkers exhibiting altered rates of acid hydrolysis: An acid-cleavable peptide linker comprising aspartic acid and proline residues is disclosed. The acid-cleavable peptide linker provides an altered sensitivity to acid-hydrolytic release of peptides of interest from fusion peptides of the formula PEP1-L-PEP2. The inventive linker, L, is described in various embodiments, each of which provides substantially more rapid... Agent: E I Du Pont De Nemours And Company

20140221607 - Monoclonal antibody and antigens for diagnosing and treating lung disease and injury: The present invention provides methods for diagnosing a patient with emphysema, COPD of lung injury caused by tobacco use by detecting the levels of EMAP II in a sample. Disclosed herein are the hypervariable regions for a rat monoclonal antibody that binds to a form of EMAP II. This disclosure... Agent: Indiana University Research And Technology Corp.

20140221609 - Activation of sodium potassium atpase: Activation sites on the alpha subunit of sodium potassium ATPase have been discovered. It has also been discovered that certain antibodies that bind to the alpha subunit of sodium potassium ATPase dramatically increase enzyme activity. There has never before been a report of precise activation sites or drug interaction sites... Agent:

20140221610 - Dispersion and detachment of cell aggregates: Compositions comprising a protein or isolated peptide, and methods using the same for preventing, dispersing or detaching a biofilm, are disclosed.... Agent: Hutchison Biofilm Medical Solutions Ltd.

20140221611 - Binding molecules for human factor viii and factor viii-like proteins: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of... Agent: Dyax Corp.

20140221612 - Peptides that selectively home to heart vasculature and related conjugates and methods: The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below.... Agent: Sanford-burnham Medical Research Institute

20140221613 - Novel modified protein comprising tandem-type multimer of mutant extracellular domain of protein g: The purpose of the present invention is: to provide an excellent protein which is further reduced in the binding property to an Fc region of an immunoglobulin and/or the binding property to an Fab region of the immunoglobulin in a weakly acidic region compared with that of a protein containing... Agent:

20140221614 - Collagen matrix with locally controlled intrafibrillar and extrafibrillar mineral content and methods of producing: A mineralized collagen matrix with an intrafibrillar and/or extrafibrillar gradient of mineralization for insertion replacement is disclosed. The intrafibrillar mineralization of the collagen matrix is formed by the addition of fetuin to the simulated body fluid. The gradient of intrafibrillar mineralization may stiffen the collagen matrix and simulate a natural... Agent: The Washington University

20140221615 - Porous scaffold material, and method for producing same: Provided are a scaffold material that functions as a scaffold material for two weeks or more in vivo and causes substantially no foreign-body reaction, and a method for producing the scaffold material. Specifically, a porous scaffold material comprising collagen fibers is provided.... Agent: Kyoto University

20140221616 - Haptens of quetiapine: The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from quetiapine. The invention also relates to conjugates of a quetiapine hapten and a protein.... Agent: Janssen Pharmaceutica Nv

20140221617 - Canola protein product with low phytic acid content (\"c702\"): Canola protein products having a protein content of at least about 60 wt % (N×6.25) d.b., preferably at least about 90 wt %, more preferably at lease about 100 wt %, and low phytic acid content, are produced by extracting canola seeds or canola oil seed meal with an aqueous... Agent:

20140221618 - Targeted coagulation factors and method of using the same: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the... Agent:

20140221619 - Methods and compositions for increasing protein production: The disclosure provides methods and materials for increasing the expression of a protein of interest such as an antibody by a cell. ABC50 expression or activity is increased which increases expression of the protein or antibody of interest. The disclosure also provides methods and materials for increasing the sensitivity of... Agent: University Health Network

20140221620 - Anti-human p-cadherin (cdh3) recombinant antibody: It is an object to provide a recombinant antibody that is an anti-CDH3 antibody having cytotoxicity on CDH3-expressing cells, which is anticipated to have fewer side effects than antibodies derived from animals other than humans and to maintain its therapeutic effects for a long period of time. The present invention... Agent: Perseus Proteomics Inc.

20140221624 - Humanization of rabbit antibodies using a universal antibody framework: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.... Agent: Esbatech - A Novartis Company LLC

20140221623 - Interleukin-6 receptor binding polypeptides: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as... Agent: Ablynx N.v.

20140221622 - Monovalent binding proteins: Engineered monovalent binding proteins that bind to one or more ligands (such as an antigen) via one binding domain are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.... Agent: Abbvie, Inc.

20140221621 - Single-chain multivalent binding protein compositions and methods: Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scDVD and scDVDFab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display).... Agent: Abbvie, Inc.

20140221625 - B cell lineage based immunogen design with humanized animals: Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are... Agent:

20140221626 - Compositions and methods for detection of methadone metabolite: Methods and reagents are disclosed for conducting assays for EDDP. The reagents include a moiety selected from the group consisting of poly(amino acid) label moieties, non-poly(amino acid) label moieties, poly(amino acid) immunogenic carriers, non-poly(amino acid) immunogenic carriers, non-label poly(amino acid) moieties, and non-immunogenic carrier poly(amino acid) moieties linked to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine... Agent: Siemens Healthcare Diagnostics Inc.

20140221627 - Methods for preparation of fucose-linked site specific conjugates of proteins with toxins, adjuvants, detection labels and pharmacokinetic half life extenders: The present invention relates to eukaryotic cells for producing molecules having an atypical fucose analogue on their glycomoieties and/or amino acids. It also relates to methods for producing molecules having an atypical fucose analogue on their glycomoieties and/or amino acids and to molecules obtainable by said methods. It further relates... Agent: Probiogen Ag

20140221628 - Influenza virus-like particles comprising adjuvant-fused m2 protein to enhance the immunogenicity of vaccine: A DNA vaccine comprising hyperglycosylated mutant HA gene, which is derived from avian influenza virus, is provided. A DNA vaccine composition comprising: (a) the DNA vaccine; and (b) a booster is also provided. An influenza virus-like particle comprising adjuvant-fused M2 protein is further provided. A method for eliciting an immune... Agent: National Tsing Hua University

20140221629 - Ultrafiltration membranes and methods of making: The present invention is an integral multilayered composite membrane having at least one ultrafiltration layer made by cocasting or sequentially casting a plurality of polymer solutions onto a support to form a multilayered liquid sheet and immersing the sheet into a liquid coagulation bath to effect phase separation and form... Agent: Emd Millipore Corporation

20140221630 - Method and system for processing of aquatic species: Disclosed herein is a method and system of recovering multiple products from industrial-scale production of a biomass of an aquatic species.... Agent: Pa LLC

  
07/31/2014 > 25 patent applications in 18 patent subcategories.
  
07/24/2014 > 14 patent applications in 11 patent subcategories.

20140206836 - Novel n- and c-terminal substituted antagonistic analogs of gh-rh: There is provided a novel series of synthetic analogs of hGH-RH(1-29)NH2 (SEQ ID NO: 1) and hGH-RH(1-30)NH2. Of particular interest are those carrying PhAc, N-Me-Aib, Dca, Ac-Ada, Fer, Ac-Amc, Me-NH-Sub, PhAc-Ada, Ac-Ada-D-Phe, Ac-Ada-Phe, Dca-Ada, Dca-Amc, Nac-Ada, Ada-Ada, or CH3—(CH2)10—CO-Ada, at the N-Terminus and β-Ala, Amc, Apa, Ada, AE2A, AE4P, ε-Lys(α-NH2),... Agent: University Of Miami

20140206837 - Targeting vector-phospholipid conjugates: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in... Agent: Bracco Suisse Sa

20140206838 - Compositions and methods for recognition of rna using triple helical peptide nucleic acids: Peptide nucleic acids containing thymidine and 2-aminopyridine (M) nucleobases formed stable and sequence selective triple helices with double stranded RNA at physiologically relevant conditions. The M-modified PNA displayed unique RNA selectivity by having two orders of magnitude higher affinity for the double stranded RNAs than for the same DNA sequences.... Agent: The Research Foundation For The State University Of New York

20140206839 - Cross linked hyaluronic acid-silk and uses thereof: The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents,... Agent: Allergan, Inc.

20140206840 - Fluorescent labeling of living cells: e

20140206841 - Peptide synthesis apparatus and methods using infrared energy: Apparatus and methods utilizing infrared energy for heating reactions associated with peptide synthesis, such as activation, deprotection, coupling, and cleavage. Thorough agitation of the contents of reaction vessels during heating and real-time monitoring and adjustment of temperature and/or reaction duration are also described. Existing peptide synthesizers may be retrofitted to... Agent: Protein Technologies, Inc.

20140206842 - Peptides modified with triterpenoids and small organic molecules: synthesis and use in cosmeceutical: The present invention relates to the Synthesis of Triterpenoid peptides and mechanism of action for Anti ageing and skin care. The present invention is directed towards anti-aging skin care compositions comprising peptides which are made by linking herbal actives to a pentapeptide for enhanced anti ageing activity by regenerating the... Agent:

20140206843 - Therapeutic trail fusion protein and preparation and use thereof: This invention relates to the biotechnology area, and provides a kind of TRAIL chimeric protein, DNA sequence encoding this chimeric protein, vectors comprising this DNA, host cells or transgenic animals that contain one of the vectors, and preparation methods for the said chimeric protein and its applications. The said TRAIL... Agent: Magellan Pharma Co. Ltd.

20140206844 - Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material: Described is a method for isolating multiple blood products from a single starting material. Isolation of multiple blood products from a single starting material maximizes the efficiency of blood product isolation. In the present invention, one or more blood products are isolated from a blood product material previously depleted of... Agent: Prothera Biologics

20140206845 - Stable protein-containing preparation containing argininamide or analogous compound thereof: Addition of argininamide or valinamide to a highly concentrated antibody solution was found to lead to remarkable stabilization, in particular, stabilization against photostress.... Agent: Chugai Seiyaku Kabushiki Kaisha

20140206846 - Dual targeting: The present invention relates to antibody-based dual targeting molecules, and to methods for generating such dual targeting molecules, including a library-based approach.... Agent:

20140206847 - Mutant protein capable of binding specifically and quickly to troponin i derived from human myocardium: Provided is a mutant protein capable of binding specifically and quickly to troponin I derived from human myocardium. The mutant protein comprises a first mutant scFv antibody fragment 51 a second mutant scFv antibody fragment 52 and a linker 53. The first mutant scFv antibody fragment 51 comprises a first... Agent: Panasonic Corporation

20140206848 - Oligosaccharide modification and labeling of proteins: The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention.... Agent: Life Technologies Corporation

20140206849 - Antibodies having reduced immunogenicity in a human: The disclosure relates to engineered antibodies that when administered to a human, exhibit a low level of immunogenicity in the human. The disclosure also relates to methods for generating the antibodies. The engineered antibodies can be derived from, e.g., on-human (e.g., murine) donor antibodies or from chimeric or humanized antibodies... Agent: Alexion Pharmaceuticals, Inc.

  
07/17/2014 > 7 patent applications in 6 patent subcategories.

20140200329 - Bisaminoethanethiol-targeting ligand conjugates and compositions: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a... Agent: Board Of Regents, The University Of Texas System

20140200330 - Isolation of phosphoproteins, glycoproteins and fragments thereof: The invention provides methods and apparatus for the selective isolation of phosphorylated and glycosylated proteins and their fragments. A lanthanide metal cation is used to precipitate proteins or protein fragments containing phospho groups and/or glyco groups. The sample preparation method can be used for many types of biological samples, including... Agent:

20140200331 - Engineered immunoglobulin heavy chain-light chain pairs and uses thereof: The present invention provides heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the CH1 and/or CL domains, amino acid modifications in... Agent: Zymeworks Inc.

20140200332 - Low dose methods for treating disorders in which tnf-alpha activity is detrimental: A method of treating TNFα disorders is described, wherein the method comprises administering a low dose amount of a TNFα inhibitor.... Agent: Abbvie Biotechnology Ltd.

20140200333 - Dendron reporter molecules: Dendronic reporters are described which incorporate a high density of luminescent or non-luminescent dyes at periphery sites and a focal point group that is reactive, ionic or a conjugated substance. Such dendronic reporters are capable of sensing analytes, or are otherwise useful in luminescent assays. Additionally, methods of synthesis are... Agent: Seta Biomedicals, LLC

20140200335 - Catalytic biomass conversion: A biorefining method of processing a lignocellulosic biomass to separate lignin and hemicellulose from cellulose includes the steps of (a) reacting the biomass in an aqueous slurry having a pH less than 7, comprising a transition metal catalyst, hydrogen peroxide; and (b) separating a solid cellulose fraction from dissolved lignin... Agent: Nano-green Biorefineries Inc.

20140200334 - Process for treating lignin: A process for recovery of lignin from black liquor that contains either soluble or dispersed lignin by generating a “liquid lignin” at high yield is disclosed. Soluble lignin at a high pH is precipitated by reducing the pH of the black liquor stream by countercurrent reaction with carbon dioxide, at... Agent: Liquid Lignin Company, LLC

Previous industry: Synthetic resins or natural rubbers -- part of the class 520 series
Next industry: Organic compounds -- part of the class -570 series


######

RSS FEED for 20140807: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents we recommend signing up for free keyword monitoring by email.



Results in 0.33112 seconds

PATENT INFO